Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies

MLA

Goswami, Pushpendra, et al. “Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies.” Blood, vol. 132, no. Supplement 1, Nov. 2018, p. 2294. EBSCOhost, https://doi.org/10.1182/blood-2018-99-117094.

APA

Goswami, P., Oliva, E. N., Ionova, T., & Salek, S. (2018). Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies. Blood, 132(Supplement 1), 2294. https://doi.org/10.1182/blood-2018-99-117094

Chicago

Goswami, Pushpendra, Esther Natalie Oliva, Tatyana Ionova, and Sam Salek. 2018. “Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies.” Blood 132 (Supplement 1): 2294. doi:10.1182/blood-2018-99-117094.